# prior inadequate response to oral CGRP inhibitors FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors

> No upcoming FDA catalysts in prior inadequate response to oral CGRP inhibitors; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for prior inadequate response to oral CGRP inhibitors?

No upcoming FDA catalysts in prior inadequate response to oral CGRP inhibitors; 3 past events are recorded. Press release filed with the SEC (EX-99): "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" [Calendar and source filings](https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors)

Source: Press release filed with the SEC (EX-99), accession 0000950170-25-021801, https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm (retrieved 2026-11-12). Last confirmed 2025-02-18. Cite: https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2025 | [SYMBRAVO® (meloxicam-rizatriptan) topline data readout](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "Topline results of EMERGE Phase 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm)) |
| Q1 2025 | [SUNOSI® (solriamfetol) topline data readout](https://sec-api.dev/pdufa/solriamfetol) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm)) |
| 2H 2025 | [SUNOSI® (solriamfetol) NDA/BLA submission](https://sec-api.dev/pdufa/solriamfetol) | AXSM | prior inadequate response to oral CGRP inhibitors | scheduled | "NDA submission anticipated in 2H 2025 Topline results of FOCUS and PARADIGM Ph 3 trials of solriamfetol in ADHD and MDD, respectively, on track for 1Q 2025 Topline results from EMERGE Ph 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025 Expanding commercial success Financial strength and operational excellence *Product revenue growth vs. comparable periods in 2023" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm)) |

## Drugs

- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan) (AXSM)
- [SUNOSI® (solriamfetol)](https://sec-api.dev/pdufa/solriamfetol) (AXSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "prior inadequate response to oral CGRP inhibitors FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors

```bibtex
@misc{secapidev_indications_prior_inadequate_response_to_oral_cgrp_inhibitors_20261116,
  title        = {prior inadequate response to oral CGRP inhibitors FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_prior_inadequate_response_to_oral_cgrp_inhibitors_20261116","title":"prior inadequate response to oral CGRP inhibitors FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
